Ultragenyx Pharmaceutical (RARE) Assets Average (2014 - 2026)

Ultragenyx Pharmaceutical (RARE) has 13 years of Assets Average data on file, last reported at $1.4 billion in Q1 2026.

• Quarterly Assets Average changed 0.46% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (changed 0.46% YoY) and the FY2025 annual result came in at $1.5 billion, up 1.37% from the prior year.
• Assets Average improved to $1.4 billion in Q1 2026 per RARE's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.6 billion in Q4 2022 and bottomed at $1.2 billion in Q3 2025.
• The 5-year median for Assets Average is $1.4 billion (2025), against an average of $1.4 billion.
• The widest annual swing landed in 2024, when Assets Average grew 23.82%; it then retreated 20.91% in 2025.
• Tracing RARE's Assets Average over 5 years: stood at $1.6 billion in 2022, then declined by 13.74% to $1.4 billion in 2023, then climbed by 11.44% to $1.5 billion in 2024, then decreased by 10.49% to $1.4 billion in 2025, then advanced by 3.88% to $1.4 billion in 2026.
• Per Business Quant, the three latest RARE Assets Average figures stand at $1.4 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.2 billion (Q3 2025).

Peer Comparison